EMA/680100/2012

European Medicines Agency decision

P/0260/2012

of 19 November 2012

on the granting of a product specific waiver for alpha1-proteinase inhibitor (EMEA-001312-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0260/2012

of 19 November 2012

on the granting of a product specific waiver for alpha1-proteinase inhibitor (EMEA-001312-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by CSL Behring GmbH on 2 July 2012 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 5 October 2012 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.

(2) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A waiver for alpha1-proteinase inhibitor, powder and solvent for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to CSL Behring GmbH, Emil-von-Behring-Strasse 76, 35041 – Marburg, Germany.

Done at London, 19 November 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/488199/2012

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMEA-001312-PIP01-12

Scope of the application

Active substance(s):

Alpha1-proteinase inhibitor

Condition(s):

Treatment of liver disease due to alpha1-antitrypsin deficiency

Treatment of chronic obstructive pulmonary disease due to alpha1-antitrypsin deficiency

Pharmaceutical form(s):

Powder and solvent for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

CSL Behring GmbH

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, CSL Behring GmbH submitted to the European Medicines Agency on 2 July 2012 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 9 August 2012.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population and Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 5 October 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition: treatment of liver disease due to alpha1-antitrypsin deficiency

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- for powder and solvent for solution for infusion, intravenous use;
- on the grounds that the specific medicinal product is likely to be ineffective;

1.2. Condition: treatment of chronic obstructive pulmonary disease due to alpha1-antitrypsin deficiency

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- for powder and solvent for solution for infusion, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended only occurs in adults.